Department of Epidemiology and Population Health, Albert Einstein College of Medicine, Bronx, NY 10461, USA.
J Oncol. 2011;2011:970804. doi: 10.1155/2011/970804. Epub 2011 Aug 22.
Mutations in the p53 tumor suppressor gene and accumulation of its protein in breast tissue are thought to play a role in breast carcinogenesis. However, few studies have prospectively investigated the association of p53 immunopositivity and/or p53 alterations in women with benign breast disease in relation to the subsequent risk of invasive breast cancer. We carried out a case-control study nested within a large cohort of women biopsied for benign breast disease in order to address this question. After exclusions, 491 breast cancer cases and 471 controls were available for analysis. Unconditional logistic regression was used to estimate odds ratios (OR) and 95% confidence intervals (95% CI). Neither p53 immunopositivity nor genetic alterations in p53 (either missense mutations or polymorphisms) was associated with altered risk of subsequent breast cancer. However, the combination of both p53 immunopositivity and any p53 nucleotide change was associated with an approximate 5-fold nonsignificant increase in risk (adjusted OR 4.79, 95% CI 0.28-82.31) but the confidence intervals were extremely wide. Our findings raise the possibility that the combination of p53 protein accumulation and the presence of genetic alterations may identify a group at increased risk of breast cancer.
p53 肿瘤抑制基因的突变及其蛋白在乳腺组织中的积累被认为在乳腺癌的发生中起作用。然而,很少有前瞻性研究调查 p53 免疫阳性和/或 p53 改变与良性乳腺疾病女性随后发生浸润性乳腺癌的风险之间的关系。我们进行了一项病例对照研究,该研究嵌套在一个大型良性乳腺疾病活检女性队列中,以解决这个问题。排除后,共有 491 例乳腺癌病例和 471 例对照可供分析。采用非条件逻辑回归估计比值比(OR)和 95%置信区间(95%CI)。p53 免疫阳性和 p53(错义突变或多态性)的遗传改变均与随后发生乳腺癌的风险改变无关。然而,p53 免疫阳性和任何 p53 核苷酸改变的组合与风险增加约 5 倍(调整后的 OR 4.79,95%CI 0.28-82.31)但置信区间非常宽。我们的发现提出了这样一种可能性,即 p53 蛋白积累和遗传改变的组合可能确定一组乳腺癌风险增加的人群。